CA2783107C - Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other c2-domain containing proteins - Google Patents

Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other c2-domain containing proteins Download PDF

Info

Publication number
CA2783107C
CA2783107C CA2783107A CA2783107A CA2783107C CA 2783107 C CA2783107 C CA 2783107C CA 2783107 A CA2783107 A CA 2783107A CA 2783107 A CA2783107 A CA 2783107A CA 2783107 C CA2783107 C CA 2783107C
Authority
CA
Canada
Prior art keywords
seq
protein
epitope
ferlin
apicomplexan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2783107A
Other languages
English (en)
French (fr)
Other versions
CA2783107A1 (en
Inventor
Ann-Kristin Mueller
Eva Morath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universität Heidelberg
Original Assignee
Universität Heidelberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universität Heidelberg filed Critical Universität Heidelberg
Publication of CA2783107A1 publication Critical patent/CA2783107A1/en
Application granted granted Critical
Publication of CA2783107C publication Critical patent/CA2783107C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2783107A 2009-12-05 2010-12-06 Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other c2-domain containing proteins Expired - Fee Related CA2783107C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26702609P 2009-12-05 2009-12-05
US61/267,026 2009-12-05
PCT/EP2010/007399 WO2011066995A1 (en) 2009-12-05 2010-12-06 Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other c2-domain containing proteins

Publications (2)

Publication Number Publication Date
CA2783107A1 CA2783107A1 (en) 2011-06-09
CA2783107C true CA2783107C (en) 2018-08-07

Family

ID=43499977

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2783107A Expired - Fee Related CA2783107C (en) 2009-12-05 2010-12-06 Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other c2-domain containing proteins

Country Status (8)

Country Link
US (1) US8968750B2 (cg-RX-API-DMAC10.html)
EP (1) EP2507259B1 (cg-RX-API-DMAC10.html)
JP (1) JP2013512866A (cg-RX-API-DMAC10.html)
CN (1) CN102781958B (cg-RX-API-DMAC10.html)
BR (1) BR112012013581A8 (cg-RX-API-DMAC10.html)
CA (1) CA2783107C (cg-RX-API-DMAC10.html)
MX (1) MX2012006458A (cg-RX-API-DMAC10.html)
WO (1) WO2011066995A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012076157A2 (en) 2010-12-06 2012-06-14 Ruprecht-Karls-Universität Heidelberg Malaria vaccines based on pre-erythrocytic antigens from p. falciparum
EP2941269B1 (en) * 2013-01-07 2020-12-09 Mucosal Vaccine Technologies LLC Therapeutic vaccines for treating herpes simplex virus type 2 infections
CA2957722C (en) 2014-08-19 2022-05-31 Merck Sharp & Dohme Corp. Anti-tigit antibodies
CN115925931A (zh) 2015-08-14 2023-04-07 默沙东公司 抗tigit抗体
JP2017210441A (ja) * 2016-05-26 2017-11-30 国立大学法人大阪大学 マラリアワクチン

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518528A (en) * 1983-05-19 1985-05-21 Rasnick David W α Amino fluoro ketones
US5198334A (en) * 1989-07-21 1993-03-30 Terumo Corporation Protection of natural killer cell cytolytic activity in peripheral blood mononuclear cells
GB9406492D0 (en) * 1994-03-31 1994-05-25 Isis Innovation Malaria peptides
AU5931698A (en) * 1997-01-21 1998-08-07 New York University Universal t-cell epitopes for anti-malarial vaccines
US20030077653A1 (en) * 2000-04-20 2003-04-24 The University Of Georgia Research Foundation, Inc. Method for the identification of active site protease inactivators
US7811575B2 (en) * 2001-04-10 2010-10-12 Agensys, Inc. Nucleic acids and corresponding proteins entitled 158P3D2 useful in treatment and detection of cancer
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
CA2409897A1 (en) * 2002-10-25 2004-04-25 Institut Pasteur Plasmodium falciparum virulence factor var o
US7198791B2 (en) * 2003-03-03 2007-04-03 Pluschke, Gerd Et Al. Compositions and methods for the generation of protective immune responses against malaria
US8206725B2 (en) * 2003-08-26 2012-06-26 The Council Of The Queensland Institute Of Medical Research Immunogenic agent and pharmaceutical composition for use against homologous and heterologous pathogens including plasmodium SPP
US20090324628A1 (en) * 2003-12-30 2009-12-31 Kobenhavns Universitet Panium Compounds useful in the diagnosis and treatment of malaria
JP4834671B2 (ja) * 2005-09-29 2011-12-14 株式会社マルハニチロ水産 成人病の予防及び治療に有効な組成物
GB0601059D0 (en) * 2006-01-19 2006-03-01 Univ Durham Target
WO2009082440A2 (en) * 2007-12-18 2009-07-02 Vaxinnate Corporation Compositions of toll-like receptor agonists and malaria antigens and methods of use
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
WO2011085070A2 (en) * 2010-01-06 2011-07-14 Virginia Tech Intellectual Properties, Inc. Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts
WO2012076157A2 (en) * 2010-12-06 2012-06-14 Ruprecht-Karls-Universität Heidelberg Malaria vaccines based on pre-erythrocytic antigens from p. falciparum

Also Published As

Publication number Publication date
EP2507259B1 (en) 2016-08-24
CA2783107A1 (en) 2011-06-09
WO2011066995A1 (en) 2011-06-09
BR112012013581A2 (pt) 2017-01-10
US8968750B2 (en) 2015-03-03
EP2507259A1 (en) 2012-10-10
CN102781958B (zh) 2017-07-11
JP2013512866A (ja) 2013-04-18
US20120308598A1 (en) 2012-12-06
MX2012006458A (es) 2012-09-07
BR112012013581A8 (pt) 2017-12-26
CN102781958A (zh) 2012-11-14

Similar Documents

Publication Publication Date Title
Kaneko et al. The high molecular mass rhoptry protein, RhopH1, is encoded by members of the clag multigene family in Plasmodium falciparum and Plasmodium yoelii
US8470560B2 (en) CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
López et al. What is known about the immune response induced by Plasmodium vivax malaria vaccine candidates?
EP1573012B1 (en) Recombinant viral-based malaria vaccines
Haussig et al. Inactivation of a Plasmodium apicoplast protein attenuates formation of liver merozoites
Calvo-Calle et al. A linear peptide containing minimal T-and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge
US11944674B2 (en) Vaccines
EP2956166B1 (en) Genetic attenuation of plasmodium by b9 gene disruption
EP2507259B1 (en) Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other c2-domain containing proteins
DK2453914T3 (en) ANTIGEN-SPECIFIC MULTIPLE PIT-BASED ANTI-INFECTIOUS VACCINES
TW200416043A (en) Epstein barr virus peptide epitopes, polyepitopes and delivery system therefor
Cherif et al. Nanoparticle formulation enhanced protective immunity provoked by PYGPI8p-transamidase related protein (PyTAM) DNA vaccine in Plasmodium yoelii malaria model
US9314517B2 (en) Parasite vaccine
Hollingdaleª et al. Immune Responses to Liver-Stage Parasites: Implications for Vaccine ati
Scorza et al. Induction of strain-transcending immunity against Plasmodium chabaudi adami malaria with a multiepitope DNA vaccine
EP2409987B1 (en) Ribosomal P protein complex from Plasmodium falciparum as antigen in vaccines against malaria
Mehrizi et al. Immune responses elicited by co‐immunization of Plasmodium vivax and P. falciparum MSP‐1 using prime‐boost immunization strategies
JP5573679B2 (ja) マラリアワクチン組成物および細胞媒介免疫性を惹起する成分
WO2017190154A2 (en) Hybrid hepadnavirus cores carrying multiple malaria parasite epitopes
Weiss et al. Differential effects of C3d on the immunogenicity of gene gun vaccines encoding Plasmodium falciparum and Plasmodium berghei MSP142
Dobaño et al. Identification of minimal CD8+ and CD4+ T cell epitopes in the Plasmodium yoelii hepatocyte erythrocyte protein 17 kDa
Hetttihewa Immunization of retrovirus-transfected dendritic cells induces specific cytotoxic T lymphocytes for two distinct malarial peptides presented by Kd molecule
WO2023012354A1 (en) Genetically modified plasmodium parasite expressing il-6 – use to raise an immune response in a host against malaria at the pre-erythrocytic stage of development of the parasite
CN104736710A (zh) 来自恶性疟原虫的p47(pfs47)或来自间日疟原虫的p47(pvs47)作为疫苗或药物筛选靶标用于抑制人疟疾传播的用途
Espinosa et al. Development of a Chimeric Development of a Chimeric Plasmodium berghei Plasmodium berghei Strain Expressing the Repeat Region of the Expressing the Repeat Region of the P. vivax Circumsporozoite Circumsporozoite Protein for Protein for In Vivo Evaluation of Vaccine Efficacy Evaluation of Vaccine Efficacy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20151117

MKLA Lapsed

Effective date: 20210831

MKLA Lapsed

Effective date: 20191206